Close Menu

blindness

CRISPR for Blindness

According to the Associated Press, a patient has undergone gene editing to treat an inherited form of blindness.

Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.

The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.

The first trial using CRISPR within the human body is to begin this fall to treat a form of blindness.

 

The therapy treats a form of childhood blindness and, if approved, would be the first approved gene therapy in the US.

US Food and Drug Administration advisors are to weigh gene therapy for blindness, according to Reuters.

Researchers describe a rare genetic disorder that leads to deafness, blindness, and albinism, that's more likely among children of deaf parents, the Washington Post reports.

Researchers have sequenced and analyzed more than 50 feral and domestic cats in search of genetic variants involved in specific physical features and forms of disease. 

Researchers find that a woman's genetic risk for age-related macular degeneration is influenced by lifestyle factors.

Avellino Laboratory, a South Korean and Japanese company offering genetic testing for a disorder called avellino corneal dystrophy, has received CLIA certification to test patients in the US to determine whether they are carriers for ACD and should therefore avoid LASIK and other

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.